Natriumvalproaat Sandoz (Sodium Valproate)

Sodium valproate raises brain levels of the inhibitory neurotransmitter GABA by enhancing its synthesis and reducing its breakdown, while also blocking voltage‑gated sodium channels. These actions together dampen neuronal excitability and help prevent the rapid firing that underlies seizures and mood swings.

The appropriate dose of Natriumvalproaat Sandoz is determined individually by a qualified prescriber based on the patient’s age, weight, clinical condition, and response to therapy. Dosage adjustments are made according to therapeutic monitoring and tolerability.

Sodium valproate is classified as pregnancy Category X because it carries a high risk of major congenital malformations and developmental disorders. It is contraindicated in pregnancy and should be avoided during breastfeeding unless the benefits clearly outweigh the risks and a specialist advises otherwise.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with agents such as carbamazepine or lamotrigine, sodium valproate offers broad-spectrum seizure control and mood‑stabilising properties but has a higher risk of hepatic and hematologic adverse effects. Choice of therapy depends on the specific seizure type, comorbidities, and individual safety considerations.

Store Natriumvalproaat Sandoz at room temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight and excessive heat to maintain stability and potency.

The medication is administered orally. Patients should swallow the tablet whole with a glass of water, preferably with food to reduce gastrointestinal irritation, unless the prescriber provides alternative instructions.

Serious risks include liver injury, pancreatitis, severe skin reactions such as Stevens‑Johnson syndrome, and life‑threatening hyperammonemic encephalopathy. Prompt medical attention is required if symptoms such as jaundice, severe abdominal pain, rash, or sudden confusion develop.

Patients who are pregnant, have known hypersensitivity to valproate, have severe hepatic impairment, or have diagnosed mitochondrial disorders or urea‑cycle defects should avoid using Natriumvalproaat Sandoz. A healthcare professional should evaluate suitability before initiating therapy.